Endotronix Presents Positive PROACTIVE-HF Clinical Trial Results for its Cordella Pulmonary Artery Sensor

The trial met primary safety and efficacy endpoints, demonstrating a markedly low rate of heart failure hospitalizations for NYHA class III HF patients.The results support the company's pre-market approval (PMA) application for U.S. market access, which is under review with the U.S. Food and Drug Administration (FDA).View original content:https://www.prnewswire.co.uk/news-releases/endotronix-presents-positive-proactive-hf-clinical-trial-results-for-its-cordella-pulmonary-artery-sensor-302080677.html

@ prnewswire.co.uk

Hol dir den Wissensvorsprung der Profis. Seit 2005 liefert der Börsenbrief trading-notes verlässliche Trading-Empfehlungen – dreimal die Woche, direkt in dein Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr.
Jetzt anmelden.